A Phase 3 interventional study of Nivolumab and Brentuximab vedotin in Hodgkin's Disease, sponsored by Bristol-Myers Squibb. Terminated at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.
Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 42nd largest by enrollment, is one of 9 that started in 2017, is one of 3 in phase 3, and was the 15th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
National Research Center for Hematology, Russia · Sites in Russia
Ages 18–60
National Medical Research Radiological Centre of the Ministry of Health of Russia · Sites in Russia
Ages 18+
University of Washington · Sites in United States
Ages 18+
St. Petersburg State Pavlov Medical University · Sites in Russia
Ages 18–60
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 45 · Phase 3 5
First in 2012; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 52 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
16 studies in Hodgkin Disease by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Hodgkin Disease by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2017, is the only one in phase 3, and was the 15th registered.
Bristol-Myers Squibb’s Hodgkin Disease studies by the year they started, since 2005.
8 of the studies testing nivolumab in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT03033914Memorial Sloan Kettering Cancer CenterA(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | 2027-01 |
| NCT02940301Ohio State University Comprehensive Cancer CenterIbrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | 2027-02-15 |
| NCT05162976City of Hope Medical CenterCC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | 2027-04-27 |
| NCT05272384National Cancer Institute (NCI)Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | 2027-06-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 52 studies testing nivolumab in Hodgkin Disease, from their registry updates:
Among Bristol-Myers Squibb’s 16 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are with one of the following:.
i) stem cell transplant (ASCT) ineligible patients.
ii) Patients after failure of ASCT.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab combined with Brentuximab
Biological: Nivolumab · Biological: Brentuximab vedotin
Brentuximab alone
Biological: Brentuximab vedotin
Specified dose on specified days
Also known as: Opdivo
Specified dose on specified days
Also known as: Adcetris
Progression Free Survival (PFS)
Progression Free Survival (PFS) is defined as time from date of randomization to death, or disease progression per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method.
Time frame: From randomization to date of death, or disease progression (up to approximately 45 months)
Complete Response Rate (CRR):
Complete Response Rate (CRR) is defined as the number of participants who have achieved complete response (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
Time frame: From randomization up to approximately 45 months
Objective Response Rate (ORR)
Objective Response Rate (ORR) is defined as the number of participants with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
Time frame: From randomization up to approximately 45 months
Duration of Response (DOR)
The time from first response (Complete response (CR) or partial response (PR)) to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
Time frame: From randomization to date of documented progression or death (up to approximately 45 months)
Duration of Complete Response (DOCR)
Duration of complete response (DOR) is defined as the time from first complete response to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
Time frame: From randomization to date of documented progression or death (up to approximately 45 months)
Overall Survival (OS)
Overall Survival (OS) is defined as the time between the date of randomization and the date of death estimated using the Kaplan-Meier (KM) product-limit method
Time frame: From randomization to the date of death (up to approximately 3 years 7 months)
| Milestone | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Started | 12 | 11 |
| Completed | 3 | 1 |
| Not completed | 9 | 10 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Participants withdrew consent | 1 | 0 |
| Withdrew: Participant discontinued study before treatment | 0 | 1 |
| Withdrew: Disease progression | 2 | 6 |
| Withdrew: Study drug toxicity | 2 | 2 |
| Withdrew: Participant request to discontinue study treatment | 1 | 1 |
| Withdrew: Other reasons | 2 | 0 |
Progression Free Survival (PFS) is defined as time from date of randomization to death, or disease progression per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method.
| Months | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Progression Free Survival (PFS) | 14.32 (10.12 to NA) | 7.93 (2.86 to NA) |
Complete Response Rate (CRR) is defined as the number of participants who have achieved complete response (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
| Participants | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Complete Response Rate (CRR): | 4 | 3 |
Objective Response Rate (ORR) is defined as the number of participants with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) (Lugano 2014 classification) per investigator assessment. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
| Participants | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Objective Response Rate (ORR) | 8 | 5 |
The time from first response (Complete response (CR) or partial response (PR)) to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Partial response is considered a score of 4 or 5. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
| Months | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Duration of Response (DOR) | 11.27 (7.39 to 11.27) | 7.00 (1.54 to NA) |
Duration of complete response (DOR) is defined as the time from first complete response to the date of initial objectively documented progression (2014 Lugano classification) or death due to any cause per investigator assessment estimated using the Kaplan-Meier (KM) product-limit method. Complete response is considered a score of 1, 2, or 3. Per the Lugano criteria: Positron emission tomography (PET) negative scans are defined on the 5-point scale as scores of 1, 2, or 3 (where 1 = no uptake above background; 2 = uptake \</= mediastinum; and 3 = uptake \> mediastinum but \</= liver) and PET-positive scans, as scores of 4 or 5 (where 4 = uptake moderately higher than liver; 5 = uptake markedly higher than liver and/or new lesions). Response on PET scans should be reported as complete metabolic response (CMR) partial metabolic response (PMR), SMD (stable metabolic disease), or PMD (progressive metabolic disease).
| Months | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Duration of Complete Response (DOCR) | 7.85 (NA to NA) | NA (NA to NA) |
Overall Survival (OS) is defined as the time between the date of randomization and the date of death estimated using the Kaplan-Meier (KM) product-limit method
| Months | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Overall Survival (OS) | NA (25.40 to NA) | NA (NA to NA) |
Collected over From first dose to up to 100 days post last dose (up to approximately 2 years) All-cause mortality was assessed from date of first dose to study completion (up to approximately 3 years 7 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + Brentuximab Vedotin (BV) | 1/12 (8.3%) | 6/12 (50%) | 12/12 (100%) |
| Brentuximab Vedotin (BV) | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Event | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 2/12 | 0/10 |
| Non-cardiac chest painGeneral disorders | 0/12 | 1/10 |
| EmbolismVascular disorders | 0/12 | 1/10 |
| PyrexiaGeneral disorders | 1/12 | 0/10 |
| Adenovirus infectionInfections and infestations | 1/12 | 0/10 |
| Herpes zosterInfections and infestations | 1/12 | 0/10 |
| SeizureNervous system disorders | 1/12 | 0/10 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/12 | 0/10 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/12 | 0/10 |
| RashSkin and subcutaneous tissue disorders | 1/12 | 0/10 |
| Event | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) |
|---|---|---|
| Neuropathy peripheralNervous system disorders | 6/12 | 6/10 |
| FatigueGeneral disorders | 6/12 | 4/10 |
| HeadacheNervous system disorders | 6/12 | 2/10 |
| ConstipationGastrointestinal disorders | 5/12 | 1/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/12 | 2/10 |
| NauseaGastrointestinal disorders | 4/12 | 4/10 |
| PruritusSkin and subcutaneous tissue disorders | 1/12 | 4/10 |
| Non-cardiac chest painGeneral disorders | 4/12 | 0/10 |
| PyrexiaGeneral disorders | 4/12 | 2/10 |
| Peripheral sensory neuropathyNervous system disorders | 4/12 | 1/10 |
| Age, Continuous(Years) | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) | Total |
|---|---|---|---|
| Mean | 37.5 ± 13.1 | 42.3 ± 16.1 | 39.8 ± 14.5 |
| Sex: Female, Male(Participants) | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 7 | 8 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 9 | 7 | 16 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Nivolumab + Brentuximab Vedotin (BV) | Brentuximab Vedotin (BV) | Total |
|---|---|---|---|
| WHITE | 7 | 4 | 11 |
| BLACK OR AFRICAN AMERICAN | 3 | 2 | 5 |
| JAPANESE | 0 | 1 | 1 |
| ASIAN OTHER | 0 | 1 | 1 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 1 | 0 | 1 |
| OTHER | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Feb 2021, 43 months.
Results were first posted in Apr 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Brentuximab Vedotin